Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study

BACKGROUND: Patients with chronic migraine (CM) treated with eptinezumab in the PROMISE-2 trial achieved greater reductions in migraine and headache frequency, impact, and acute headache medication (AHM) use than did patients who received placebo. This post hoc analysis examines relationships betwee...

Descripción completa

Detalles Bibliográficos
Autores principales: Cowan, Robert P., Marmura, Michael J., Diener, Hans-Christoph, Starling, Amaal J., Schim, Jack, Hirman, Joe, Brevig, Thomas, Cady, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446734/
https://www.ncbi.nlm.nih.gov/pubmed/36068494
http://dx.doi.org/10.1186/s10194-022-01482-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446734/
https://www.ncbi.nlm.nih.gov/pubmed/36068494
http://dx.doi.org/10.1186/s10194-022-01482-0

Ejemplares similares